Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells.

Misek SA, Appleton KM, Dexheimer TS, Lisabeth EM, Lo RS, Larsen SD, Gallo KA, Neubig RR.

Oncogene. 2019 Oct 28. doi: 10.1038/s41388-019-1074-1. [Epub ahead of print]

PMID:
31659259
2.

Loss-of-function mutations in human RGS2 differentially regulate pharmacological reactivity of resistance vasculature.

Phan HTN, Jackson WF, Shaw V, Watts SW, Neubig RR.

Mol Pharmacol. 2019 Oct 23. pii: mol.119.116822. doi: 10.1124/mol.119.116822. [Epub ahead of print]

3.

An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19.

Shaw VS, Mohammadi M, Quinn JA, Vashisth H, Neubig RR.

Mol Pharmacol. 2019 Dec;96(6):683-691. doi: 10.1124/mol.119.117176. Epub 2019 Sep 22.

PMID:
31543506
4.

Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay.

Benham V, Bullard B, Dexheimer TS, Bernard MP, Neubig RR, Liby KT, Bernard JJ.

Sci Rep. 2019 Jul 16;9(1):10278. doi: 10.1038/s41598-019-46531-y.

5.

Spermine in semen of male sea lamprey acts as a sex pheromone.

Scott AM, Zhang Z, Jia L, Li K, Zhang Q, Dexheimer T, Ellsworth E, Ren J, Chung-Davidson YW, Zu Y, Neubig RR, Li W.

PLoS Biol. 2019 Jul 9;17(7):e3000332. doi: 10.1371/journal.pbio.3000332. eCollection 2019 Jul.

6.

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.

Lionarons DA, Hancock DC, Rana S, East P, Moore C, Murillo MM, Carvalho J, Spencer-Dene B, Herbert E, Stamp G, Damry D, Calado DP, Rosewell I, Fritsch R, Neubig RR, Molina-Arcas M, Downward J.

Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.

7.

The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice.

Leal AS, Misek SA, Lisabeth EM, Neubig RR, Liby KT.

Sci Rep. 2019 May 8;9(1):7072. doi: 10.1038/s41598-019-43430-0.

8.

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Kahl DJ, Hutchings KM, Lisabeth EM, Haak AJ, Leipprandt JR, Dexheimer T, Khanna D, Tsou PS, Campbell PL, Fox DA, Wen B, Sun D, Bailie M, Neubig RR, Larsen SD.

J Med Chem. 2019 May 9;62(9):4350-4369. doi: 10.1021/acs.jmedchem.8b01772. Epub 2019 Apr 18.

9.

A Two-Pulse Cellular Stimulation Test Elucidates Variability and Mechanisms in Signaling Pathways.

Sumit M, Jovic A, Neubig RR, Takayama S, Linderman JJ.

Biophys J. 2019 Mar 5;116(5):962-973. doi: 10.1016/j.bpj.2019.01.022. Epub 2019 Jan 30.

PMID:
30782397
10.

Mouse models of GNAO1-associated movement disorder: Allele- and sex-specific differences in phenotypes.

Feng H, Larrivee CL, Demireva EY, Xie H, Leipprandt JR, Neubig RR.

PLoS One. 2019 Jan 25;14(1):e0211066. doi: 10.1371/journal.pone.0211066. eCollection 2019.

11.

Interplay of cysteine exposure and global protein dynamics in small-molecule recognition by a regulator of G-protein signaling protein.

Mohammadi M, Mohammadiarani H, Shaw VS, Neubig RR, Vashisth H.

Proteins. 2019 Feb;87(2):146-156. doi: 10.1002/prot.25642. Epub 2018 Dec 26.

PMID:
30521141
12.

In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis.

Tagalakis AD, Madaan S, Larsen SD, Neubig RR, Khaw PT, Rodrigues I, Goyal S, Lim KS, Yu-Wai-Man C.

J Nanobiotechnology. 2018 Nov 27;16(1):97. doi: 10.1186/s12951-018-0425-3.

13.

Interpreting Hydrogen-Deuterium Exchange Events in Proteins Using Atomistic Simulations: Case Studies on Regulators of G-Protein Signaling Proteins.

Mohammadiarani H, Shaw VS, Neubig RR, Vashisth H.

J Phys Chem B. 2018 Oct 11;122(40):9314-9323. doi: 10.1021/acs.jpcb.8b07494. Epub 2018 Oct 1.

14.

Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive Gαi2 protein.

Senese NB, Oginsky M, Neubig RR, Ferrario C, Jutkiewicz EM, Traynor JR.

Neuropharmacology. 2018 Oct;141:296-304. doi: 10.1016/j.neuropharm.2018.09.002. Epub 2018 Sep 4.

15.

A mechanistic review on GNAO1-associated movement disorder.

Feng H, Khalil S, Neubig RR, Sidiropoulos C.

Neurobiol Dis. 2018 Aug;116:131-141. doi: 10.1016/j.nbd.2018.05.005. Epub 2018 May 24. Review.

PMID:
29758257
16.

Differential Protein Dynamics of Regulators of G-Protein Signaling: Role in Specificity of Small-Molecule Inhibitors.

Shaw VS, Mohammadiarani H, Vashisth H, Neubig RR.

J Am Chem Soc. 2018 Mar 7;140(9):3454-3460. doi: 10.1021/jacs.7b13778. Epub 2018 Feb 26.

17.

Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80.

Dripps IJ, Boyer BT, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM.

Br J Pharmacol. 2018 Mar;175(6):891-901. doi: 10.1111/bph.14131. Epub 2018 Feb 9.

18.

Human Missense Mutations in Regulator of G Protein Signaling 2 Affect the Protein Function Through Multiple Mechanisms.

Phan HTN, Sjögren B, Neubig RR.

Mol Pharmacol. 2017 Oct;92(4):451-458. doi: 10.1124/mol.117.109215. Epub 2017 Aug 7.

PMID:
28784619
19.

Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations.

Feng H, Sjögren B, Karaj B, Shaw V, Gezer A, Neubig RR.

Neurology. 2017 Aug 22;89(8):762-770. doi: 10.1212/WNL.0000000000004262. Epub 2017 Jul 26.

20.

Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis.

Yu-Wai-Man C, Spencer-Dene B, Lee RMH, Hutchings K, Lisabeth EM, Treisman R, Bailly M, Larsen SD, Neubig RR, Khaw PT.

Sci Rep. 2017 Mar 31;7(1):518. doi: 10.1038/s41598-017-00212-w.

21.

The DRY motif and the four corners of the cubic ternary complex model.

Rovati GE, Capra V, Shaw VS, Malik RU, Sivaramakrishnan S, Neubig RR.

Cell Signal. 2017 Jul;35:16-23. doi: 10.1016/j.cellsig.2017.03.020. Epub 2017 Mar 24. Review.

PMID:
28347873
22.

Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma.

Hutchings KM, Lisabeth EM, Rajeswaran W, Wilson MW, Sorenson RJ, Campbell PL, Ruth JH, Amin A, Tsou PS, Leipprandt JR, Olson SR, Wen B, Zhao T, Sun D, Khanna D, Fox DA, Neubig RR, Larsen SD.

Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. doi: 10.1016/j.bmcl.2017.02.070. Epub 2017 Mar 10.

23.

A central role for R7bp in the regulation of itch sensation.

Pandey M, Zhang JH, Mishra SK, Adikaram PR, Harris B, Kahler JF, Loshakov A, Sholevar R, Genis A, Kittock C, Kabat J, Ganesan S, Neubig RR, Hoon MA, Simonds WF.

Pain. 2017 May;158(5):931-944. doi: 10.1097/j.pain.0000000000000860.

24.

Regulator of G Protein Signaling 6 Protects the Heart from Ischemic Injury.

Rorabaugh BR, Chakravarti B, Mabe NW, Seeley SL, Bui AD, Yang J, Watts SW, Neubig RR, Fisher RA.

J Pharmacol Exp Ther. 2017 Mar;360(3):409-416. doi: 10.1124/jpet.116.238345. Epub 2016 Dec 29.

25.

Optimisation of Intestinal Fibrosis and Survival in the Mouse S. Typhimurium Model for Anti-fibrotic Drug Discovery and Preclinical Applications.

Johnson LA, Rodansky ES, Moons DS, Larsen SD, Neubig RR, Higgins PDR.

J Crohns Colitis. 2017 Jun 1;11(6):724-736. doi: 10.1093/ecco-jcc/jjw210.

26.

Chemerin-induced arterial contraction is Gi- and calcium-dependent.

Ferland DJ, Darios ES, Neubig RR, Sjögren B, Truong N, Torres R, Dexheimer TS, Thompson JM, Watts SW.

Vascul Pharmacol. 2017 Jan;88:30-41. doi: 10.1016/j.vph.2016.11.009. Epub 2016 Nov 24.

27.

Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.

Haak AJ, Appleton KM, Lisabeth EM, Misek SA, Ji Y, Wade SM, Bell JL, Rockwell CE, Airik M, Krook MA, Larsen SD, Verhaegen M, Lawlor ER, Neubig RR.

Mol Cancer Ther. 2017 Jan;16(1):193-204. doi: 10.1158/1535-7163.MCT-16-0482. Epub 2016 Nov 11.

28.

The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Dripps IJ, Wang Q, Neubig RR, Rice KC, Traynor JR, Jutkiewicz EM.

Psychopharmacology (Berl). 2017 Jan;234(1):29-39. doi: 10.1007/s00213-016-4432-5. Epub 2016 Sep 13.

29.

Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks.

Evelyn CR, Lisabeth EM, Wade SM, Haak AJ, Johnson CN, Lawlor ER, Neubig RR.

Microarrays (Basel). 2016 May 28;5(2). pii: E13. doi: 10.3390/microarrays5020013.

30.

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ.

Neuron. 2016 Jun 1;90(5):1139. doi: 10.1016/j.neuron.2016.05.017. No abstract available.

31.

Digoxin-Mediated Upregulation of RGS2 Protein Protects against Cardiac Injury.

Sjögren B, Parra S, Atkins KB, Karaj B, Neubig RR.

J Pharmacol Exp Ther. 2016 May;357(2):311-9. doi: 10.1124/jpet.115.231571. Epub 2016 Mar 3.

32.

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ.

Neuron. 2015 Nov 18;88(4):762-73. doi: 10.1016/j.neuron.2015.10.039. Erratum in: Neuron. 2016 Jun 1;90(5):1139.

33.

RGS Proteins and Gαi2 Modulate Sleep, Wakefulness, and Disruption of Sleep/ Wake States after Isoflurane and Sevoflurane Anesthesia.

Zhang H, Wheat H, Wang P, Jiang S, Baghdoyan HA, Neubig RR, Shi XY, Lydic R.

Sleep. 2016 Feb 1;39(2):393-404. doi: 10.5665/sleep.5450.

34.

Band-pass processing in a GPCR signaling pathway selects for NFAT transcription factor activation.

Sumit M, Neubig RR, Takayama S, Linderman JJ.

Integr Biol (Camb). 2015 Nov;7(11):1378-86. doi: 10.1039/c5ib00181a.

35.

RGS-Insensitive G Proteins as In Vivo Probes of RGS Function.

Neubig RR.

Prog Mol Biol Transl Sci. 2015;133:13-30. doi: 10.1016/bs.pmbts.2015.04.010. Epub 2015 Jun 6. Review.

PMID:
26123300
36.

FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex.

Sjögren B, Swaney S, Neubig RR.

PLoS One. 2015 May 13;10(5):e0123581. doi: 10.1371/journal.pone.0123581. eCollection 2015.

37.

Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors.

Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, Wang Q, Huang XP, Traynor JR, Husbands SM, Morari M, Neubig RR.

ACS Chem Neurosci. 2015 Jun 17;6(6):911-9. doi: 10.1021/acschemneuro.5b00063. Epub 2015 Apr 20.

PMID:
25844489
38.

Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis.

Sisson TH, Ajayi IO, Subbotina N, Dodi AE, Rodansky ES, Chibucos LN, Kim KK, Keshamouni VG, White ES, Zhou Y, Higgins PD, Larsen SD, Neubig RR, Horowitz JC.

Am J Pathol. 2015 Apr;185(4):969-86. doi: 10.1016/j.ajpath.2014.12.005. Epub 2015 Feb 11.

39.

Induction of the matricellular protein CCN1 through RhoA and MRTF-A contributes to ischemic cardioprotection.

Zhao X, Ding EY, Yu OM, Xiang SY, Tan-Sah VP, Yung BS, Hedgpeth J, Neubig RR, Lau LF, Brown JH, Miyamoto S.

J Mol Cell Cardiol. 2014 Oct;75:152-61. doi: 10.1016/j.yjmcc.2014.07.017. Epub 2014 Aug 8.

40.

Identification of protein kinase C activation as a novel mechanism for RGS2 protein upregulation through phenotypic screening of natural product extracts.

Raveh A, Schultz PJ, Aschermann L, Carpenter C, Tamayo-Castillo G, Cao S, Clardy J, Neubig RR, Sherman DH, Sjögren B.

Mol Pharmacol. 2014 Oct;86(4):406-16. doi: 10.1124/mol.114.092403. Epub 2014 Aug 1.

41.

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.

Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP, Sexton PM, Kenakin TP, Ehlert FJ, Spedding M, Langmead CJ.

Pharmacol Rev. 2014 Oct;66(4):918-47. doi: 10.1124/pr.114.008862.

PMID:
25026896
42.

Conditional disruption of interactions between Gαi2 and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury.

Parra S, Huang X, Charbeneau RA, Wade SM, Kaur K, Rorabaugh BR, Neubig RR.

BMC Pharmacol Toxicol. 2014 Jun 5;15:29. doi: 10.1186/2050-6511-15-29.

43.

Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

Tsou PS, Haak AJ, Khanna D, Neubig RR.

Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C2-13. doi: 10.1152/ajpcell.00060.2014. Epub 2014 Apr 16. Review.

44.

Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.

Haak AJ, Tsou PS, Amin MA, Ruth JH, Campbell P, Fox DA, Khanna D, Larsen SD, Neubig RR.

J Pharmacol Exp Ther. 2014 Jun;349(3):480-6. doi: 10.1124/jpet.114.213520. Epub 2014 Apr 4.

45.

Gain-of-function mutation in Gnao1: a murine model of epileptiform encephalopathy (EIEE17)?

Kehrl JM, Sahaya K, Dalton HM, Charbeneau RA, Kohut KT, Gilbert K, Pelz MC, Parent J, Neubig RR.

Mamm Genome. 2014 Jun;25(5-6):202-10. doi: 10.1007/s00335-014-9509-z. Epub 2014 Apr 5.

46.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

47.

Redox modification of nuclear actin by MICAL-2 regulates SRF signaling.

Lundquist MR, Storaska AJ, Liu TC, Larsen SD, Evans T, Neubig RR, Jaffrey SR.

Cell. 2014 Jan 30;156(3):563-76. doi: 10.1016/j.cell.2013.12.035. Epub 2014 Jan 16.

48.

Regulation of protease-activated receptor 1 signaling by the adaptor protein complex 2 and R4 subfamily of regulator of G protein signaling proteins.

Chen B, Siderovski DP, Neubig RR, Lawson MA, Trejo J.

J Biol Chem. 2014 Jan 17;289(3):1580-91. doi: 10.1074/jbc.M113.528273. Epub 2013 Dec 2.

49.

Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.

Johnson LA, Rodansky ES, Haak AJ, Larsen SD, Neubig RR, Higgins PD.

Inflamm Bowel Dis. 2014 Jan;20(1):154-65. doi: 10.1097/01.MIB.0000437615.98881.31.

50.

Conformational dynamics of a regulator of G-protein signaling protein reveals a mechanism of allosteric inhibition by a small molecule.

Vashisth H, Storaska AJ, Neubig RR, Brooks CL 3rd.

ACS Chem Biol. 2013 Dec 20;8(12):2778-84. doi: 10.1021/cb400568g. Epub 2013 Oct 24.

Supplemental Content

Loading ...
Support Center